Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte Anticipating Positive CHMP Opinion On Ovarian Cancer Drug/Diagnostic Combo

This article was originally published in The Pink Sheet Daily

Executive Summary

Endocyte and Merck are preparing to launch a combo drug/diagnostic in folate receptor-positive platinum-resistant ovarian cancer, a condition with a very poor survival prognosis, later this year in the EU. Medical affairs staff are meeting with specialists to discuss how the diagnostic can target patients most likely to respond in pre-approval commercial efforts.

You may also be interested in...



Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte

Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.

Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year

The U.S. biotech, which went public last year, will file EC145 and a companion diagnostic for conditional approval in Europe in platinum-resistant ovarian cancer based on findings from four Phase I and Phase II trials in the third quarter.

Akorn Defaults On Loan Agreement After Sale Bid Falls Flat

Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel